The Pharmacy Times® Pharmacy Technician Clinical Role section is a comprehensive resource for clinical news and expert insights on issues pertaining to specialty pharmacists.
November 20th 2024
Bimekizumab-bkzx is the first and only approved medication that targets both interleukin (IL) 17F and IL-17A.
November 13th 2024
FDA Fast Tracks Padeliporfin Immune Photo Activated Cancer Therapy for Upper-Tract Urothelial Cancer
January 19th 2021A minimally invasive, targeted treatment option, ImPACT is also under evaluation in patients with other localized tumors, such as urothelial cancer, esophageal cancer, lung cancer, and pancreatic cancer.
Read More
Study: Biologic Therapy for Psoriasis May Reduce Heart Disease
January 12th 2021The current study provides characterization of a lipid-rich necrotic core, a dangerous type of coronary plaque made up of dead cells and cell debris that is prone to rupture, which can lead to a heart attack or stroke.
Read More
Risankizumab Demonstrates Significant Improvements In Patients with Crohn Disease
January 11th 2021A significantly greater proportion of patients with Crohn disease achieved both primary endpoints with overall safety results generally consistent with the known safety profile of risankizumab.
Read More
FDA Grants Rare Disease Designations to Novel Agent That May Directly Elicit Tumor Cell Death
January 8th 2021FDA approves request submitted by Moleculin Biotech, Inc. for rare disease designations to be granted their drug candidate that appears to directly elicit tumor cell death and prompt the immune system to eliminate tumors.
Read More
Pharmacist Burnout: A Cry for a Transformative Approach to Traditional Pharmacy Practice
January 7th 2021Pharmacists must juggle the delicate balance of integrating clinical services into traditional dispensing environments, while being forced into performance metrics set forth by corporate entities.
Read More
Study: Statins May Protect the Heart from Chemotherapy Treatment of Early Breast Cancer
January 7th 2021According to the study authors, previous small studies suggested that women taking statins may have less heart muscle damage from these types of chemotherapy, yet the exact mechanisms of how statins protect against the cardiac cell damage remains unknown.
Read More
FDA Grants Breakthrough Designation to Tiragolumab Plus Atezolizumab for NSCLC
January 7th 2021The FDA has granted a breakthrough therapy designation to tiragolumab for use in combination with atezolizumab (Tecentriq) in the frontline treatment of patients with metastatic non­–small cell lung cancer.
Read More